Business Context and Reporting Period
Hercules Capital, Inc. (HTGC) is a specialty finance company and Business Development Company (BDC) focused on providing senior secured loans to high-growth, venture capital-backed companies in technology, life sciences, and sustainable/renewable technology sectors. This Form 10-Q covers the quarterly period ended June 30, 2021.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 |
|---|---|---|
| Total Investment Income | $138.3 million | $141.6 million |
| Net Investment Income | $71.5 million | $76.3 million |
| Net Increase in Net Assets from Operations | $146.9 million | $33.0 million |
| Net Asset Value (NAV) per Share | $11.71 | $10.19 |
| Total Investments (Fair Value) | $2.52 billion | $2.35 billion |
| Total Debt (Carrying Value) | $1.18 billion | $1.29 billion |
| Cash and Cash Equivalents | $18.4 million | $35.9 million |
| Distributions Paid per Share | $0.76 | $0.72 |
Material Changes vs. Prior Period
- Portfolio Growth: Total investment portfolio fair value increased by approximately $167 million (7.1%) from December 31, 2020, driven by new fundings and unrealized appreciation.
- Realized Gains/Losses: The company reported a net realized loss of $6.5 million for the six months ended June 30, 2021, compared to a net realized gain of $7.1 million in the prior year period. This was primarily due to a $62.1 million write-off of the investment in Solar Spectrum Holdings LLC (Sungevity), partially offset by $55.6 million in realized gains from sales (notably DoorDash and TransMedics).
- Unrealized Appreciation: Net unrealized appreciation on investments was $81.9 million for the six months ended June 30, 2021, a significant improvement from $50.3 million of net unrealized depreciation in the same period in 2020.
- Debt Reduction: Total debt decreased by approximately $109 million. The company paid down $99.0 million of SBA Debentures (winding down HT III) and reduced principal on 2027 and 2028 Asset-Backed Notes by $63.1 million and $53.5 million, respectively.
- Operating Expenses: Net operating expenses increased slightly to $66.8 million from $65.3 million, driven by higher employee compensation and stock-based compensation, partially offset by lower legal expenses.
Guidance, Outlook, and Risks
- Outlook: Management continues to monitor the impact of the COVID-19 pandemic on portfolio companies. The company maintains ample liquidity with approximately $610 million available, including cash and borrowing capacity under credit facilities and SBA licenses.
- Yield Metrics: The weighted average core yield on the debt portfolio was 11.5%, and the effective yield was 12.7% for the six months ended June 30, 2021.
- Portfolio Composition: The portfolio remains concentrated in Drug Discovery & Development (31.3%), Software (26.8%), and Internet Consumer & Business Services (25.0%).
- Risks: Key risks include the performance of significant portfolio companies (six investments represent >5% of net assets), interest rate fluctuations (96.8% of debt is floating rate), and the potential for further write-offs in the biotech and technology sectors.
- Subsequent Events: On July 1, 2021, the company fully redeemed $75.0 million of April 2025 Notes. On July 21, 2021, the Board declared a cash distribution of $0.32 per share.
Investor Verification Checklist
- Write-off Impact: Verify the specific details and remaining exposure related to the $62.1 million write-off of Solar Spectrum Holdings LLC.
- Concentration Risk: Review the financial health of the top six portfolio companies (BridgeBio, Worldremit, Rocket Lab, EverFi, Houzz, uniQure), which collectively represent over 39% of net assets.
- Debt Maturity Wall: Assess the refinancing needs for the $230 million of 2022 Convertible Notes and $150 million of 2022 Notes maturing in 2022.
- Unfunded Commitments: Confirm the company's ability to fund the $327.3 million in unfunded contractual commitments available at the request of portfolio companies.
- NAV vs. Market Price: Compare the reported NAV of $11.71 per share against the market trading price to evaluate the discount/premium.